Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news
Author:
Publisher
Elsevier BV
Subject
Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference89 articles.
1. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: renal, penile, and testicular tumours;Moch;Eur Urol.,2016
2. Updated european association of urology guidelines on renal cell carcinoma: Immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma;Albiges;Eur Urol.,2019
3. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Escudier;Ann Oncol.,2019
4. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma;Fisher;Cancer J Sci Am.,2000
5. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy;Fyfe;J Clin Oncol Off J Am Soc Clin Oncol.,1995
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial;European Urology;2024-08
2. Progression-Free Survival and Treatment-Free Interval in Head and Neck Cancer with Long-Term Response to Nivolumab: Timing of Active Discontinuation;Cancers;2024-07-12
3. Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma;Journal of Clinical Medicine;2024-01-05
4. NKG2A+CD8+T cells infiltration determines immunosuppressive contexture and inferior response to immunotherapy in clear cell renal cell carcinoma;Journal for ImmunoTherapy of Cancer;2024-01
5. Discontinuation of anti‑programmed cell death protein 1 immune checkpoint inhibition after complete remission in head and neck squamous cell carcinoma: A case report and literature review;Oncology Letters;2023-09-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3